UNICA IRIS Institutional Research Information System

ONALI, SARA
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
EU - Europa 63.739
NA - Nord America 3.277
AS - Asia 2.054
SA - Sud America 420
AF - Africa 69
OC - Oceania 10
Continente sconosciuto - Info sul continente non disponibili 4
Totale 69.573
Salva come PNG Salva come JPEG
Nazione #
IT - Italia 62.907
US - Stati Uniti d'America 3.222
SG - Singapore 945
CN - Cina 479
BR - Brasile 322
VN - Vietnam 275
SE - Svezia 251
FI - Finlandia 140
DE - Germania 124
FR - Francia 99
HK - Hong Kong 90
GB - Regno Unito 69
IN - India 44
AR - Argentina 41
BD - Bangladesh 40
KR - Corea 24
PL - Polonia 24
ZA - Sudafrica 24
IQ - Iraq 23
MX - Messico 23
CA - Canada 22
TR - Turchia 18
ES - Italia 17
NL - Olanda 17
AT - Austria 15
RU - Federazione Russa 15
EC - Ecuador 14
ID - Indonesia 14
SA - Arabia Saudita 14
JP - Giappone 13
PK - Pakistan 13
MA - Marocco 12
UZ - Uzbekistan 12
IE - Irlanda 11
CO - Colombia 10
UA - Ucraina 9
CL - Cile 8
EG - Egitto 8
PH - Filippine 8
PY - Paraguay 8
KE - Kenya 7
MY - Malesia 7
VE - Venezuela 7
AU - Australia 6
TN - Tunisia 6
CZ - Repubblica Ceca 5
GR - Grecia 5
HU - Ungheria 5
AZ - Azerbaigian 4
BO - Bolivia 4
ET - Etiopia 4
IL - Israele 4
BE - Belgio 3
BG - Bulgaria 3
CH - Svizzera 3
DZ - Algeria 3
IR - Iran 3
KZ - Kazakistan 3
LU - Lussemburgo 3
RS - Serbia 3
AL - Albania 2
DK - Danimarca 2
DO - Repubblica Dominicana 2
EU - Europa 2
FJ - Figi 2
GY - Guiana 2
KG - Kirghizistan 2
LA - Repubblica Popolare Democratica del Laos 2
LB - Libano 2
LK - Sri Lanka 2
NP - Nepal 2
NZ - Nuova Zelanda 2
PE - Perù 2
RO - Romania 2
SV - El Salvador 2
UY - Uruguay 2
XK - ???statistics.table.value.countryCode.XK??? 2
AE - Emirati Arabi Uniti 1
AM - Armenia 1
AO - Angola 1
BB - Barbados 1
BH - Bahrain 1
BN - Brunei Darussalam 1
CI - Costa d'Avorio 1
GA - Gabon 1
GE - Georgia 1
GT - Guatemala 1
HR - Croazia 1
JM - Giamaica 1
JO - Giordania 1
KH - Cambogia 1
LT - Lituania 1
LV - Lettonia 1
MK - Macedonia 1
NG - Nigeria 1
NI - Nicaragua 1
OM - Oman 1
PA - Panama 1
PS - Palestinian Territory 1
QA - Qatar 1
Totale 69.569
Salva come PNG Salva come JPEG
Città #
Cagliari 60.807
Uta 1.921
Ashburn 563
Singapore 507
Fairfield 276
San Jose 217
Nyköping 204
Dallas 182
Boardman 167
Seattle 118
Helsinki 115
Wilmington 115
Chandler 105
Houston 105
Woodbridge 104
Cambridge 102
Council Bluffs 92
Los Angeles 84
Ho Chi Minh City 82
Hong Kong 80
Santa Clara 76
New York 68
Beijing 64
Lauterbourg 63
Boston 56
Dong Ket 52
Hanoi 46
Redwood City 46
Hefei 41
The Dalles 39
Ann Arbor 35
Rome 32
São Paulo 31
Hangzhou 30
Buffalo 29
Munich 27
Redondo Beach 25
Frankfurt am Main 22
London 22
Seoul 22
San Diego 21
Warsaw 20
Shanghai 19
Orem 17
Chicago 15
Turku 14
Atlanta 13
Tokyo 13
Belo Horizonte 12
Guangzhou 12
Stockholm 12
Haiphong 11
Lappeenranta 11
Montreal 11
Nuremberg 11
Baghdad 10
Johannesburg 10
Milan 10
Phoenix 10
Tashkent 10
Vienna 10
Da Nang 9
Jacksonville 9
Mexico City 9
Nanjing 9
Rio de Janeiro 9
Chennai 8
Düsseldorf 8
Elk Grove Village 8
Mountain View 8
Salvador 8
Amsterdam 7
Denver 7
Dublin 7
Manchester 7
Tianjin 7
Beachwood 6
Brasília 6
Brooklyn 6
Casablanca 6
Dalian 6
Madrid 6
Nairobi 6
Salt Lake City 6
San Francisco 6
Wuhan 6
Brno 5
Bắc Ninh 5
Chattanooga 5
Columbus 5
Curitiba 5
Jeddah 5
Jiaxing 5
Naples 5
New Delhi 5
Newark 5
Ninh Bình 5
Poplar 5
Quito 5
Redmond 5
Totale 67.294
Salva come PNG Salva come JPEG
Nome #
IBD Flare in the COVID-19 Pandemic: Therapy Discontinuation Is to Blame 9.047
Comparative Efficacy of Vedolizumab and Adalimumab in Ulcerative Colitis Patients Previously Treated With Infliximab 2.129
An Objective Comparison of Vedolizumab and Ustekinumab Effectiveness in Crohn's Disease Patients' Failure to TNF-Alpha Inhibitors 2.104
Colonic phenotype of the ileum in Crohn's disease: A prospective study before and after ileocolonic resection 1.995
Ileal lesions in patients with ulcerative colitis after ileo-rectal anastomosis: Relationship with colonic metaplasia 1.860
Phase I clinical trial of Smad7 knockdown using antisense oligonucleotide in patients with active Crohn's disease 1.637
Impact of a multidisciplinary approach in enteropathic spondyloarthritis patients 1.592
Response Assessed by Ultrasonography as Target of Biological Treatment for Crohn's Disease 1.582
Switching from IFX originator to biosimilar CT-P13 does not impact effectiveness,safety and immunogenicity in a large cohort of IBD patients 1.546
The Resolution of Intestinal Inflammation: The Peace-Keeper's Perspective 1.542
Steroid-free remission and closure of recto-vaginal fistula using adalimumab in a Crohn's disease patient naïve to anti-tumour necrosis factor alpha antibodies 1.479
Cancer and immunomodulators in inflammatory bowel diseases 1.364
Mongersen, an oral SMAD7 antisense oligonucleotide, and Crohn's disease 1.337
A phase 1 open-label trial shows that smad7 antisense oligonucleotide (GED0301) does not increase the risk of small bowel strictures in Crohn's disease 1.332
Adalimumab in active ulcerative colitis: A "real-life" observational study 1.200
Psoriasis phenotype in inflammatory bowel disease: A case-control prospective study 1.199
Small bowel capsule endoscopy vs conventional techniques in patients with symptoms highly compatible with Crohn's Disease 1.199
Tbet Expression in Regulatory T Cells Is Required to Initiate Th1-Mediated Colitis 1.172
Endoscopic vs ultrasonographic findings related to Crohn's Disease recurrence: A prospective longitudinal study at 3 years 1.155
Anti-TNF-alpha treatments and obstructive symptoms in Crohn's Disease: A prospective study 1.122
The Italian clinical experience with adalimumab in Crohn's disease: Eleven clinical cases 1.080
A novel Smad7 genetic variant mapping on the genomic region targeted by Mongersen is associated with Crohn's disease 1.076
Dual Targeted Therapy: a possible option for the management of refractory Inflammatory Bowel Disease 1.060
Female reproductive health and inflammatory bowel disease: A practice-based review 1.055
Tumor infiltrating regulatory t cells in sporadic and colitis-associated colorectal cancer: The red little riding hood and the wolf 1.013
Early post-operative endoscopic recurrence in Crohn's disease patients: Data from an Italian Group for the study of inflammatory bowel disease (IG-IBD) study on a large prospective multicenter cohort 991
Infliximab three-dose induction regimen in severe corticosteroid-refractory ulcerative colitis: Early and late outcome and predictors of colectomy 980
GPR120/FFAR4: A Potential New Therapeutic Target for Inflammatory Bowel Disease 950
Measuring disease activity in Crohn's disease 934
Combination therapy in inflammatory bowel disease – from traditional immunosuppressors towards the new paradigm of dual targeted therapy 922
Azathioprine for prevention of clinical recurrence in Crohn's disease patients with severe endoscopic recurrence: an IG-IBD randomized double-blind trial 897
Post-operative recurrence of Crohn's disease: A prospective study at 5 years 881
TRAF3IP2 gene is associated with cutaneous extraintestinal manifestations in Inflammatory bowel disease 871
A Pharmacological Batch of Mongersen that Downregulates Smad7 is Effective as Induction Therapy in Active Crohn’s Disease: A Phase II, Open-Label Study 839
Use of biologics and small molecule drugs for the management of moderate to severe ulcerative colitis: IG-IBD clinical guidelines based on the GRADE methodology 839
Long-term safety of Infliximab for the treatment of inflammatory bowel disease: Does blocking TNFα reduce colitis-associated colorectal carcinogenesis? 838
Safety of treatments for inflammatory bowel disease: Clinical practice guidelines of the Italian Group for the Study of Inflammatory Bowel Disease (IG-IBD) 830
Comparative Effectiveness Research: A Roadmap to Sail the Seas of IBD Therapies 823
Laparoscopic versus open ileo-colonic resection in crohn's disease: Short- and long-term results from a prospective longitudinal study 800
Efficacy and safety of infliximab and adalimumab in Crohn's disease: A single centre study 791
Cancer in Crohn's disease patients treated with infliximab: A long-term multicenter matched pair study 775
Therapies for inflammatory bowel disease do not pose additional risks for adverse outcomes of SARS-CoV-2 infection: an IG-IBD study 737
Impact of COVID-19 pandemic on the daily management of biotechnological therapy in inflammatory bowel disease patients: Reorganisational response in a high-volume Italian inflammatory bowel disease centre 726
Comparison of two strategies for the management of postoperative recurrence in Crohn's disease patients with one clinical risk factor: A multicentre IG-IBD study 721
Development of a numerical index quantitating small bowel damage as detected by ultrasonography in Crohn's disease 705
Immune system and gut microbiota senescence in elderly IBD patients 705
A family study of asymptomatic small bowel Crohn's disease 698
Small intestine contrast ultrasonography vs computed tomography enteroclysis for assessing ileal Crohn's disease 682
Fistulizing pattern in Crohn's disease and pancolitis in ulcerative colitis are independent risk factors for cancer: A single-center cohort study 657
Frequency, pattern, and risk factors of postoperative recurrence of Crohn's disease after resection different from ileo-colonic 641
Accuracy of small-intestine contrast ultrasonography, compared with computed tomography enteroclysis, in characterizing lesions in patients with Crohn's disease 637
Wireless capsule endoscopy and proximal small bowel lesions in Crohn's disease 631
Frequency and pattern of endoscopic recurrence in Crohn's disease patients with ileocolonic resection using a laparoscopic versus laparotomic approach: A prospective longitudinal study 591
Non-invasive techniques for assessing postoperative recurrence in Crohn's disease 552
Wireless capsule endoscopy and small intestine contrast ultrasonography in recurrence of Crohn's disease 539
Effectiveness and safety of vedolizumab in a matched cohort of elderly and nonelderly patients with inflammatory bowel disease: the IG-IBD LIVE study 539
Severity of postoperative recurrence in Crohn's disease: Correlation between endoscopic and sonographic findings 481
Multiple Orocutaneous Extraintestinal Manifestations in Ulcerative Colitis Patient: Complete Response to Ustekinumab 457
Telemedicine in inflammatory bowel disease from its origin to the post pandemic golden age: A narrative review 424
Adherence to Mediterranean Diet and Diet Quality in Patients with Inflammatory Bowel Disease: A Single-Center, Observational, Case-Control Study 223
Italian validation of the IBD-disk tool for the assessment of disability in inflammatory bowel diseases: A cross-sectional multicenter study 193
Pragmatic Trial Design to Compare Real-world Effectiveness of Different Treatments for Inflammatory Bowel Diseases: The PRACTICE-IBD European Consensus 179
Eosinophilic esophagitis in the "atopic march": dupilumab as an "umbrella" strategy for multiple coexisting atopic diseases 139
Suboptimal disease control and contributing factors in Italian IBD patients: The IBD-PODCAST Study 138
Interplay Between Depression and Inflammatory Bowel Disease: Shared Pathogenetic Mechanisms and Reciprocal Therapeutic Impacts-A Comprehensive Review 117
Patient Satisfaction with IBD Undergoing Colonoscopy: A Multicenter Cross-Sectional Study 110
Adaptation of the European Crohn's Colitis Organisation quality of care standards to Italy: The Italian Group for the study of inflammatory bowel disease consensus 107
Xanthine Oxidase-Dependent Activation of NLPR3 Inflammasome in Epithelial Cells Sustains Inflammation in Inflammatory Bowel Disease 99
Real-world Effectiveness of Tofacitinib on Ulcerative Colitis-Associated Spondyloarthropathy: a multicenter prospective study from the Italian Group for the Study of Inflammatory Bowel Diseases (IG-IBD) 93
Real-life effectiveness and safety of tofacitinib and vedolizumab as 2nd-line for ulcerative colitis after anti-TNFs: A multicenter cohort IGIBD study (VE2TO-UC) 83
Corrigendum to "Telemedicine in inflammatory bowel disease from its origin to the post pandemic golden age: A narrative review" [Digestive and Liver Disease, Volume 56, Issue 1, January 2024, Pages 1-6] 69
Vedolizumab in inflammatory bowel disease: Real-world outcomes and their prediction with machine learning—the IG-IBD LIVE study 61
Optimizing Malnutrition Risk Detection in Inflammatory Bowel Disease: A Longitudinal Analysis of Serial Nutritional Screening Tools 59
Crohn’s disease and ulcerative colitis patient-reported outcomes signs and symptoms for the remote management of inflammatory bowel disease during the COVID-19 pandemic 58
IBD impact on quality of life and perception of disease activity in Italian patients and physicians: An IBD-PODCAST study sub analysis 54
Sequencing JAK-inhibitors in ulcerative colitis: effectiveness and safety of switching within treatment class 32
Drug-Related Pneumonitis in Patients Receiving Vedolizumab Therapy for Inflammatory Bowel Disease 11
Multicenter Real-World Outcomes of Risankizumab in Crohn's Disease: The RESOLVE IG-IBD Study 8
Ustekinumab and Janus Kinase Inhibitors Outperform Vedolizumab as Second-line Therapy in Anti-tumor Necrosis Factor-experienced Patients With Ulcerative Colitis 6
Totale 69.800
Salva come PNG Salva come JPEG
Categoria #
all - tutte 94.290
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 94.290
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2020/2021809 0 0 0 0 0 0 0 0 0 120 126 563
2021/20225.351 220 367 306 237 377 498 188 351 646 570 934 657
2022/20238.657 544 1.071 1.175 529 725 1.276 454 733 461 543 738 408
2023/20247.747 399 352 293 492 633 1.533 953 824 395 528 635 710
2024/202539.273 15.737 12.943 4.297 2.031 939 1.434 1.084 58 225 180 133 212
2025/20264.785 333 167 646 589 342 371 1.112 298 429 498 0 0
Totale 69.800